| 158.36 -5.645 (-3.44%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 198.84 | 1-year : | 232.25 |
| Resists | First : | 170.24 | Second : | 198.84 |
| Pivot price | 158.79  |
|||
| Supports | First : | 151.59 | Second : | 140.07 |
| MAs | MA(5) : | 161.23 |
MA(20) : | 155.96 |
| MA(100) : | 105.67 |
MA(250) : | 79.15 |
|
| MACD | MACD : | 6.9 |
Signal : | 8 |
| %K %D | K(14,3) : | 62.4 |
D(3) : | 68.4 |
| RSI | RSI(14): 58.9 |
|||
| 52-week | High : | 170.24 | Low : | 49 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BLTE ] has closed above bottom band by 46.9%. Bollinger Bands are 35.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 166.17 - 167.08 | 167.08 - 167.83 |
| Low: | 153.33 - 154.41 | 154.41 - 155.32 |
| Close: | 156.7 - 158.38 | 158.38 - 159.78 |
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Sat, 10 Jan 2026
Discipline and Rules-Based Execution in BLTE Response - Stock Traders Daily
Fri, 09 Jan 2026
Belite Bio Reports Breakthrough Phase 3 Results for Stargardt Disease Treatment - MSN
Fri, 09 Jan 2026
Certain Warrants of Belite Bio, Inc are subject to a Lock-Up Agreement Ending on 10-JAN-2026. - MarketScreener
Thu, 08 Jan 2026
Belite Bio stock hits all-time high at 169.88 USD - Investing.com
Tue, 06 Jan 2026
Belite Bio, Inc (BLTE) Stock Analysis: Unveiling a 15.63% Upside in Innovative Biotechnology Ventures - DirectorsTalk Interviews
Tue, 06 Jan 2026
Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 46.7 (%) |
| Held by Institutions | 13.8 (%) |
| Shares Short | 294 (K) |
| Shares Short P.Month | 290 (K) |
| EPS | -1.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.86 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.3 % |
| Return on Equity (ttm) | -32.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | 103 (M) |
| PE Ratio | -82.06 |
| PEG Ratio | 0 |
| Price to Book value | 20.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -190.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|